NYSE$DNA
Ginkgo Bioworks Holdings · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Ginkgo Bioworks reported a decrease in total revenue but an increase in foundry revenue for the fourth quarter of 2022.
Ginkgo Bioworks reported a decrease in total revenue for Q4 2022, primarily due to an expected reduction in K-12 COVID-19 testing services. However, Foundry revenue increased, and the company added 20 new Cell Programs. The company's cash balance remains strong, providing flexibility for future growth.
- Total revenue for Q4 2022 was $98 million, down 34% year-over-year.
- Foundry revenue for Q4 2022 was $53 million, up 56% year-over-year.
- Biosecurity revenue for Q4 2022 was $45 million, down 61% year-over-year.
- Loss from operations for Q4 2022 was $(235) million, compared to $(1,685) million in the prior year period.
Headline financials
Revenue & EPS history
Ginkgo Bioworks · Revenue · Quarterly
$98.3M
Forward guidance
Ginkgo expects to add 100 new Cell Programs to the Foundry platform and anticipates total revenue of at least $275 million in 2023, with Foundry revenue of at least $175 million and Biosecurity revenue of at least $100 million.
Tailwinds
- Expects to add 100 new Cell Programs to the Foundry platform in 2023.
- Anticipates total revenue of at least $275 million in 2023.
- Forecasts Foundry revenue of at least $175 million in 2023.
- Projects Biosecurity revenue of at least $100 million in 2023.
- Expects nearly half of Biosecurity revenue to come from emerging product lines.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-2.5%
Avg return
Earnings day
-8.6%
Avg return
5 days after
-12.3%
Avg return
30 days after
32%
7 / 22 earnings
Positive
+25.4%
Q4 2021
Best reaction
-20.8%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.9% | -17.5% | -19.4% | |
| Q4 2025 | +3.1% | -28.6% | -36.8% | |
| Q3 2025 | -20.8% | -26.0% | -18.1% | |
| Q1 2025 | +14.8% | +28.8% | +17.7% | |
| Q4 2024 | -11.5% | -22.2% | -40.5% | |
| Q3 2024 | -1.8% | -27.3% | +17.9% | |
| Q2 2024 | -1.5% | +2.6% | -48.4% | |
| Q1 2024 | -14.8% | -3.4% | -42.4% | |
| Q4 2023 | -15.1% | -24.3% | -23.7% | |
| Q3 2023 | -18.2% | -16.9% | -11.7% | |
| Q2 2023 | -15.9% | -13.9% | +0.0% | |
| Q1 2023 | -2.9% | -3.6% | +35.0% | |
| Q4 2022 | -4.8% | -7.5% | -9.5% | |
| Q3 2022 | -6.3% | -23.2% | -41.1% | |
| Q2 2022 | +3.0% | -21.5% | -15.4% | |
| Q1 2022 | +3.0% | -1.9% | -2.6% | |
| Q4 2021 | +25.4% | +14.8% | -6.3% | |
| Q4 2019 | -0.3% | -0.5% | -11.8% | |
| Q3 2021 | +8.5% | +4.3% | -15.9% | |
| Q2 2021 | -0.1% | -0.3% | +1.5% | |
| Q1 2021 | +0.0% | -0.2% | +0.2% | |
| Q4 2020 | +0.0% | -0.2% | +0.2% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro